Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

[1] Alejandro LM(2012)Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience J Clin Oncol 30 Abstract 294-9143

[2] Adel NG(2004)An epidermal growth factor receptor intro 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 9139-1925

[3] O’Reilly EM(2012)Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study) Ann Oncol 23 1919-298

[4] Riedel E(2012)Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study J Clin Oncol 30 Abstract 7542-1825

[5] Lacouture ME(2008)New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways Oncologist 13 289-5607

[6] Amador MR(2003)Rash severity is predictive of increased survival with erlotinib HCl Proc Am Soc Clin Oncol 22 Abstract 786-2019

[7] Oppenheimer D(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-320

[8] Perea S(2010)Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3 Cancer 116 5599-944

[9] Maitra A(2010)Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib Eur J Cancer 46 2010-1966

[10] Cusatis G(2010)First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? JOP 11 317-1554

[1] Alejandro LM(2012)Association between skin toxicities and treatment outcomes in patients with pancreatic cancer (PC) receiving erlotinib (E): Memorial Sloan-Kettering Cancer Center (MSKCC) experience J Clin Oncol 30 Abstract 294-9143

[2] Adel NG(2004)An epidermal growth factor receptor intro 1 polymorphism mediates response to epidermal growth factor receptor inhibitors Cancer Res 64 9139-1925

[3] O’Reilly EM(2012)Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study) Ann Oncol 23 1919-298

[4] Riedel E(2012)Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study J Clin Oncol 30 Abstract 7542-1825

[5] Lacouture ME(2008)New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways Oncologist 13 289-5607

[6] Amador MR(2003)Rash severity is predictive of increased survival with erlotinib HCl Proc Am Soc Clin Oncol 22 Abstract 786-2019

[7] Oppenheimer D(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-320

[8] Perea S(2010)Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3 Cancer 116 5599-944

[9] Maitra A(2010)Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib Eur J Cancer 46 2010-1966

[10] Cusatis G(2010)First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? JOP 11 317-1554